Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

EUSTAR coauthors, Pier Luigi Meroni

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.

METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses.

RESULTS: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P < 0.001). The FEV1 /FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development.

CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.

Original languageEnglish
Pages (from-to)1829-1834
Number of pages6
JournalArthritis and Rheumatology
Volume70
Issue number11
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Systemic Scleroderma
Smoking
Research
Skin Manifestations
Ulcer
History
Lung
Vital Capacity
Forced Expiratory Volume
Autoantibodies
Tobacco
Regression Analysis
Databases

Cite this

Brief Report : Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. / EUSTAR coauthors ; Meroni, Pier Luigi.

In: Arthritis and Rheumatology, Vol. 70, No. 11, 11.2018, p. 1829-1834.

Research output: Contribution to journalArticle

@article{ee9cc96811564946875960c3ab9dcb57,
title = "Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study",
abstract = "OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses.RESULTS: A total of 3,319 patients were included (mean age 57 years, 85{\%} female); 66{\%} were never smokers, 23{\%} were ex-smokers, and 11{\%} were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31{\%} versus 40{\%} and 45{\%}, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P < 0.001). The FEV1 /FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50{\%}, there was no robust adverse association of smoking with digital ulcer development.CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.",
author = "{EUSTAR coauthors} and Jaeger, {Veronika K} and Gabriele Valentini and Eric Hachulla and Franco Cozzi and Oliver Distler and Paolo Air{\'o} and Laszlo Czirj{\'a}k and Yannick Allanore and Elise Siegert and Edoardo Rosato and Marco Matucci-Cerinic and Cristian Caimmi and J{\"o}rg Henes and Carreira, {Patricia E} and Vanessa Smith and {Del Galdo}, Francesco and Denton, {Christopher P} and Susanne Ullman and {De Langhe}, Ellen and Valeria Riccieri and Alegre-Sancho, {Juan J} and Simona Rednic and Ulf M{\"u}ller-Ladner and Walker, {Ulrich A} and Meroni, {Pier Luigi}",
note = "{\circledC} 2018, American College of Rheumatology.",
year = "2018",
month = "11",
doi = "10.1002/art.40557",
language = "English",
volume = "70",
pages = "1829--1834",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Brief Report

T2 - Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

AU - EUSTAR coauthors

AU - Jaeger, Veronika K

AU - Valentini, Gabriele

AU - Hachulla, Eric

AU - Cozzi, Franco

AU - Distler, Oliver

AU - Airó, Paolo

AU - Czirják, Laszlo

AU - Allanore, Yannick

AU - Siegert, Elise

AU - Rosato, Edoardo

AU - Matucci-Cerinic, Marco

AU - Caimmi, Cristian

AU - Henes, Jörg

AU - Carreira, Patricia E

AU - Smith, Vanessa

AU - Del Galdo, Francesco

AU - Denton, Christopher P

AU - Ullman, Susanne

AU - De Langhe, Ellen

AU - Riccieri, Valeria

AU - Alegre-Sancho, Juan J

AU - Rednic, Simona

AU - Müller-Ladner, Ulf

AU - Walker, Ulrich A

AU - Meroni, Pier Luigi

N1 - © 2018, American College of Rheumatology.

PY - 2018/11

Y1 - 2018/11

N2 - OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses.RESULTS: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P < 0.001). The FEV1 /FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development.CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.

AB - OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses.RESULTS: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P < 0.001). The FEV1 /FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development.CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.

U2 - 10.1002/art.40557

DO - 10.1002/art.40557

M3 - Article

C2 - 29781588

VL - 70

SP - 1829

EP - 1834

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -